Paul Hudson

A Major Milestone for Pierre Fabre in China 🚀   I am honored to share a significant advancement for Pierre Fabre Laboratories in China 🇨🇳. Our unwavering commitment to improving patient care and advancing precision medicine has reached a pivotal moment with the recent approval of our therapeutic solution for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.   This approval, grounded in compelling results, marks a substantial improvement in overall patient survival. In China, this breakthrough aims to give hope to patients facing this challenging cancer, by reducing the risk of disease progression and enhancing their life expectancy.   Our achievement in China underscores our strategic focus on this country and our continued collaboration with healthcare professionals and authorities to make innovative treatments accessible. We are dedicated to leading the way in oncology with a robust portfolio that spans multiple therapeutic areas, addressing significant unmet medical needs. #PierreFabre #NewWaysToCare #Oncology #Innovation

557

12 commentaires

At @Laboratoires Théa, 12% of our annual turnover is reinvested into R&D to sustain a robust and diversified pipeline in eye care. The enrollment of the first patient in the Phase 2 study of TLM-003, developed in partnership with Tsubota Laboratory, Inc., is one example among many programs advancing across our portfolio.

79

1 commentaire

PMK-Group Investment Announcement I am pleased to share that PMK-Group has invested in YON E Health, a company advancing women’s health through data-driven solutions. YON E Health is developing a medical device for continuous intravaginal measurement of pH and temperature, supporting women with reliable insights into fertility, menstrual health, and preventive care. This innovation addresses an area of healthcare that has long been underserved and underfunded, despite its fundamental importance. At PMK-Group, we invest in technologies that tackle serious unmet medical needs and can be scaled into clinically meaningful solutions. Beyond capital, our role is to contribute operational, regulatory, and clinical expertise to help founders de-risk and accelerate development. Women’s health is not a niche. It is central to healthcare equity and to building systems that serve patients better. It is also personally close to me, as my PhD research focused on gynecological disorders. Supporting YON E Health reflects our conviction that strategic investment, coupled with deep clinical know-how, can bring overdue change to areas too often overlooked. I look forward to working alongside the Founder, Roswitha Verwer, and her team at YON E Health, together with our partner UniPrisma Venture Studio, with the Founders Károly Szántó and Thijmen Meijer, to help bring this important technology to patients.

52

8 commentaires

“Under the agreement, Sino Biopharmaceutical's subsidiary ​Chia Tai Tianqing Pharmaceutical Group will grant ​Sanofi an exclusive worldwide licence to develop, manufacture and commercialise rovadicitinib, receiving an upfront payment ​of $135 million.” Interestingly, that molecule has been approved recently in China. Of note as well, this is a sign of a re-Committment, at some level, to oncology by Sanofi. #china #oncology #sanofi #biopharma

27

📌 I design the scientific market architecture that enables regenerative biologics to move from lab innovation to structured international adoption. My work connects scientific structuring, clinical integration and KOL governance to ensure that complex biological technologies become clinically adoptable and market-ready across non-US regions. This is not about distribution. It is about building scientific credibility, aligning medical communication, and creating the conditions for responsible clinical adoption. This approach supports: — coherent clinical positioning — structured KOL communication — aligned distributor strategies — credible congress presence 🔬 Structured science builds structured markets 🧬 From Lab to Skin to Market 🌍 EU · MENA · APAC

2

South Korea has become a new hub for biopharmaceuticals, with the market now valued at an impressive $22 billion – on its way to becoming a global powerhouse.

15

Rottendorf Pharma brings decades of experience in late-stage development, scale-up and commercial manufacturing of oral solid dosage forms. Through this collaboration, we provide our biotech clients a continuous transition from early-stage development to commercial supply, with seamless knowledge transfer. #CorealisPharma

46

This partnership with Sun Biotech leverages our expertise in USP process development with scale-X bioreactors (Univercells Technologies, a Donaldson Life Sciences business) to advance their viral vaccine candidate. Very proud of the team, a great demonstration of CER Groupe capabilities in providing integrated #preclinical development support to our partners.

9

🇫🇷Clinical research in France takes a major step forward today. With the integration of @Gustave Roussy into our global Phase I oncology network, France now joins a network designed to accelerate first-in-human clinical studies. Behind this signature, our shared goal is clear: to shorten study start-up timelines while maintaining the highest scientific standards. ➡️This marks a decisive step in strengthening France’s position in global research, attracting new international projects, and keeping patients at the very heart of Boehringer Ingelheim’s strategy. A big thank you to all our teams and partners at Gustave Roussy for this collaboration that will shape the future of oncology research.

185

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer | AFP.com https://lnkd.in/eBbdDrUA As a board member of Agenus, I am proud that our investigational combination of botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite-stable colorectal cancer under France’s compassionate access (Accès compassionnel, or AAC) framework. This is more than a milestone for Agenus—it is a lifeline for patients and families facing one of the hardest-to-treat cancers. Published clinical data with BOT/BAL show durable responses and long term survival in this population, in fact, more than 42% of patients are alive beyond a median of 2 year follow-up. Through AAC, patients in France can now access therapy with 100% reimbursement, while hospitals and physicians receive clear guidance and support. By contrast, in the U.S., compassionate use depends on single-patient INDs (SPINDs). These require FDA approval, institutional review board sign-off, and sponsor support on a case-by-case basis. The barrier is even higher because—unlike France—U.S. law prohibits reimbursement for investigational products prior to commercial approval. Medicare, Medicaid, and private insurers cannot pay for a therapy that has not received FDA approval, even if no alternatives exist. The intent is to protect patients and payers from unproven interventions, but in practice it means the cost falls to hospitals and/or companies. Many institutions, facing regulatory and financial strain, are now declining to support SPINDs altogether. The result? U.S. patients often wait longer, face more obstacles, and sometimes miss out entirely on access to promising investigational therapies—while patients in France and elsewhere can receive care under nationally funded programs. France’s AAC shows what’s possible when policy meets innovation. The U.S. (U.S. Department of Health and Human Services (HHS and FDA) must seek a better balance—one that ensures safety and evidence generation without closing the door on hope for patients with no other options. #ImmunoOncology #PatientAccess #Policy #ColorectalCancer #Agenus

48

3 commentaires

Cutting-Edge Insights | 2025 "Immunology and Cancer" International Forum Launches in Beijing, Global Elites Jointly Explore New Horizons in Life Sciences   On October 24th, the 2025 "Immunology and Cancer" International Forum, hosted by Changping Laboratory, officially kicked off in Beijing. This landmark event has gathered a cohort of top-tier scientists from China, the United States, Japan, and Europe—including multiple recipients of the William B. Coley Award—solidifying its status as a premier "thought summit" in the immunology and cancer domain.   Nearly 30 internationally acclaimed scholars will deliver keynote presentations at the forum, with a focus on frontier areas such as pyroptosis (a key form of programmed cell death in immune response), T-cell exhaustion (a core factor limiting immunotherapy efficacy), and immune checkpoint therapy (a transformative approach in cancer treatment). These technological breakthroughs are profoundly reshaping the paradigm of cancer care and offering renewed hope to patients across the globe.   We anticipate the forum will generate more groundbreaking insights, facilitate interdisciplinary collaboration and the translation of research outcomes, and spark fresh perspectives and inspirations for professionals in the life sciences field.

3

In our world, every second counts for patients waiting for life-changing medicines. That’s why we’re excited about our latest “AI at Sanofi” episode. Discover how we're using AI to transform our Manufacturing & Supply, enabling teams to simulate, test and optimize complex processes safely without production disruptions. The real impact of our AI initiatives: ➖ Reduce deviations and improve quality ➖ Enhance yield and efficiency ➖ Accelerate time to market ➖ Strengthen sustainability across operations This isn’t just about technology, it’s about applying AI to real world challenges that directly benefit patients 💜 ⬇ Watch our new episode to see how "AI in Manufacturing & Supply" and see the difference we’re making together! ⬇ #ProudToBeSanofi #AIinHealthcare #PatientFirst

4

🗣️ "The way in which we collaborate, even if we are in different companies, can be inspiring also inside our companies." – Alice Bossi, Recordati Rare Diseases. Here is the fourth episode of #VoicesOfPartnership, our video series featuring insights from some of our trusted commercial partners. This time, Alice Bossi and Stephane Eifler from Recordati reflect on the key ingredients that make collaboration with Helsinn a success. #Partnership #Helsinn #Recordati

92

6 commentaires

"L'avenir appartient à ceux qui se lèvent tôt !" This interview on BFM Business at 6:15 is proof of that 😉 In case you missed it, you can watch the replay here : https://lnkd.in/e9CrGxWS Turning Oral RNA therapeutics into a reality requires a combination of expertise & dedication. 🧬 Thank you to the whole Oragen Therapeutics team and to all those who support us: Arnaud Beduneau Thomas Stalder Axel GUILPIN Didier Cussac Lucine Vuitton Alexander Kabanov Philippe Archinard Dr Pierre A. Morgon, PharmD, LL.M, MBA Jerome Chatelain Alexandra Monnin Stéphane CLERGET Catherine Guey Daniel Hissel Olivier Adotevi Béatrice JOLY Marc DAVID Agnès Fourcot Benjamin GOIZET Jean-François MILAN Romain LIEGE Yamina Belabassi - MBA, LL.M. Amaury Dantressangle Ludmila Monteiro Salma Amensag, PhD BENEDICTE MAGERAND Fanny Robichon Maxime Gras Sara El Jabri Simon Gudin

42

4 commentaires

France-based Servier joins the pharma corporate venture capital fray with an initial commitment of 200 million euros to invest in European biotech startups. The pharma, governed by a foundation, is one of many large drugmakers to employ the CVC model whether for financial returns, access to potential partners or future acquisition opportunities. #servier #corporateventurecapital #pharmacvc #cvc https://lnkd.in/gj8EkG-b

112

2 commentaires

Amongst many other very interesting articles and news, the latest BIOTECHFINANCES raises a question many biotechs are facing right now: how do you control clinical trial costs without weakening your study? In that discussion, CRO choice is central. There is no simple answer but, to me, if you need agility, direct access to decision-makers, and flexibility in how services are structured, a small/mid-but-global-CRO can make a lot of sense; especially when you’re running one critical study and need focus. Global presence is key though but not easy to find in smaller size CRO. But then, the real mistake is thinking this is purely a pricing decision. What truly drives cost - and risk!!! - is study design, endpoint strategy, country selection, and operational clarity. A perfectly negotiated CRO contract won’t fix a poorly framed trial. (Note that the opposite has its issues as well 😄😄). In the end, the question isn’t “small or big?” It’s: What risk are we trying to manage? And what kind of partner helps us manage it best? Bon weekend!

20

2 commentaires